Literature DB >> 25367997

The 340B discount program: outpatient prescription dispensing patterns through contract pharmacies in 2012.

Bobby L Clark1, John Hou2, Chia-Hung Chou3, Elbert S Huang4, Rena Conti5.   

Abstract

Section 340B of the Public Health Service Act provides qualified organizations serving vulnerable populations with deep discounts for some outpatient medications. A 2010 regulatory change widely expanded the 340B program's reach, allowing these organizations to contract with retail pharmacies to dispense medications for eligible patients. Little is known about which medications are dispensed by contract pharmacies under the expanded program. We provide the first comparison of 340B prescriptions and all prescriptions dispensed in contract pharmacies. We used 2012 data from Walgreens, the national leader in 340B contract pharmacies. Medications used to treat chronic conditions such as diabetes, high cholesterol levels, asthma, and depression accounted for an overwhelming majority of all prescriptions dispensed at Walgreens as part of the 340B program. A higher percentage of antiretrovirals used to treat HIV/AIDS were dispensed through 340B prescriptions than through all prescriptions dispensed at Walgreens. The majority of 340B prescriptions dispensed at Walgreens originated at tuberculosis clinics, consolidated health centers, disproportionate-share hospitals, and Ryan White clinics. Our results suggest that 340B contract pharmacies dispense medications used to treat Americans' chronic disease burden and disproportionately dispense medications used by key vulnerable populations targeted by the program. Project HOPE—The People-to-People Health Foundation, Inc.

Entities:  

Keywords:  Access To Care; Pharmaceuticals; Safety-Net Systems; Special Populations

Mesh:

Substances:

Year:  2014        PMID: 25367997      PMCID: PMC4545491          DOI: 10.1377/hlthaff.2014.0833

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  8 in total

1.  Prescription drug spending trends in the United States: looking beyond the turning point.

Authors:  Murray Aitken; Ernst R Berndt; David M Cutler
Journal:  Health Aff (Millwood)       Date:  2008-12-16       Impact factor: 6.301

2.  Exclusion of orphan drugs for certain covered entities under 340B Program. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2013-07-23

3.  Hospitals, market share, and consolidation.

Authors:  David M Cutler; Fiona Scott Morton
Journal:  JAMA       Date:  2013-11-13       Impact factor: 56.272

4.  Vertical integration: hospital ownership of physician practices is associated with higher prices and spending.

Authors:  Laurence C Baker; M Kate Bundorf; Daniel P Kessler
Journal:  Health Aff (Millwood)       Date:  2014-05       Impact factor: 6.301

5.  Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology.

Authors: 
Journal:  J Oncol Pract       Date:  2014-04-15       Impact factor: 3.840

6.  Cost consequences of the 340B drug discount program.

Authors:  Rena M Conti; Peter B Bach
Journal:  JAMA       Date:  2013-05-15       Impact factor: 56.272

7.  The impact of patient assistance programs and the 340B Drug Pricing Program on medication cost.

Authors:  Yelba M Castellon; Shahrzad Bazargan-Hejazi; Miles Masatsugu; Roberto Contreras
Journal:  Am J Manag Care       Date:  2014-02       Impact factor: 2.229

8.  Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.

Authors:  Patrick P Gleason; Catherine I Starner; Brent W Gunderson; Jeremy A Schafer; H Scott Sarran
Journal:  J Manag Care Pharm       Date:  2009-10
  8 in total
  4 in total

1.  Consequences of the 340B Drug Pricing Program.

Authors:  Sunita Desai; J Michael McWilliams
Journal:  N Engl J Med       Date:  2018-01-24       Impact factor: 91.245

2.  Assessment of US Pharmacies Contracted With Health Care Institutions Under the 340B Drug Pricing Program by Neighborhood Socioeconomic Characteristics.

Authors:  John K Lin; Pengxiang Li; Jalpa A Doshi; Sunita M Desai
Journal:  JAMA Health Forum       Date:  2022-06-17

3.  Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use.

Authors:  Lisandro D Colantonio; Shia T Kent; Meredith L Kilgore; Elizabeth Delzell; Jeffrey R Curtis; George Howard; Monika M Safford; Paul Muntner
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-01-29       Impact factor: 2.890

4.  Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV.

Authors:  Jeromie Ballreich; Timothy Levengood; Rena M Conti
Journal:  J Law Med Ethics       Date:  2022       Impact factor: 1.604

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.